[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Celularity Inc (CELU)

Celularity Inc (CELU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 53,550
  • Shares Outstanding, K 28,946
  • Annual Sales, $ 26,550 K
  • Annual Income, $ -91,720 K
  • EBIT $ -60 M
  • EBITDA $ -53 M
  • 60-Month Beta 0.54
  • Price/Sales 1.72
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 187.60% (-13.52%)
  • Historical Volatility 273.90%
  • IV Percentile 25%
  • IV Rank 11.90%
  • IV High 900.41% on 12/23/25
  • IV Low 91.28% on 09/08/25
  • Expected Move (DTE 17) 0.8075 (41.62%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 228
  • Volume Avg (30-Day) 998
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 3,224
  • Open Int (30-Day) 1,290
  • Expected Range 1.1325 to 2.7475

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-2.20
  • Growth Rate Est. (year over year) +45,509.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6400 +200.78%
on 08/03/26
2.5500 -24.51%
on 08/27/26
+1.2897 (+203.01%)
since 07/31/26
3-Month
0.5601 +243.69%
on 06/30/26
2.5500 -24.51%
on 08/27/26
+0.8550 (+79.91%)
since 06/01/26
52-Week
0.5601 +243.69%
on 06/30/26
3.1539 -38.96%
on 09/02/25
-2.0150 (-51.14%)
since 08/29/25

Most Recent Stories

More News
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform

Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products,...

CELU : 1.8900 (+2.16%)
Celularity Provides Update Regarding Nasdaq Listing Compliance

FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications...

CELU : 1.8900 (+2.16%)
CELUW : 0.0019 (+533.33%)
Celularity Provides Update Regarding Nasdaq Listing Compliance

FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it...

CELU : 1.8900 (+2.16%)
CELUW : 0.0019 (+533.33%)
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived...

CELU : 1.8900 (+2.16%)
CELUW : 0.0019 (+533.33%)
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative...

CELU : 1.8900 (+2.16%)
CELUW : 0.0019 (+533.33%)
Celularity Releases CEO Letter to Shareholders

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived...

CELU : 1.8900 (+2.16%)
CELUW : 0.0019 (+533.33%)
Celularity Releases CEO Letter to Shareholders

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (

CELU : 1.8900 (+2.16%)
CELUW : 0.0019 (+533.33%)
Celularity Appoints Rick Gonzalez as Chief Commercial Officer

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering...

CELU : 1.8900 (+2.16%)
CELUW : 0.0019 (+533.33%)
Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of...

CELU : 1.8900 (+2.16%)
CELUW : 0.0019 (+533.33%)
Celularity Receives Nasdaq Notice Regarding Form 10-Q

FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular...

CELU : 1.8900 (+2.16%)
CELUW : 0.0019 (+533.33%)

Business Summary

Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells...

See More

Key Turning Points

3rd Resistance Point 2.6672
2nd Resistance Point 2.3157
1st Resistance Point 2.0829
Last Price 1.8900
1st Support Level 1.4986
2nd Support Level 1.1471
3rd Support Level 0.9143

See More

52-Week High 3.1539
Fibonacci 61.8% 2.1631
Last Price 1.8900
Fibonacci 50% 1.8570
Fibonacci 38.2% 1.5509
52-Week Low 0.5601

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.